The European Medicines Agency, the EU's regulator for medicinal products, has approved the BioNTech-Pfizer vaccine for children aged 5-11.
The European Medicines Agency, the EU's regulator for medicinal products, on Thursday approved the BioNTech-Pfizer vaccine, also known as Comirnaty, for children aged 5-11. It's the first vaccine approved for children under 12 in the 27-member EU.
The vaccine has already been approved in the EU for use in people between the ages of 12 and 17 years since May and for adults since December 2020.
EMA said the vaccine should be given to children in two doses of 10 micrograms three weeks apart as an injection in the upper arm. Adult doses contain 30 micrograms.
"The benefits of Comirnaty in children aged 5 to 11 outweigh the risks, particularly in those with conditions that increase the risk of severe COVID-19," EMA said.
The companies said a clinical trial of children aged 5 to 11 showed their vaccine to be 90.7% effective against the coronavirus. However, the studies have not been large enough to determine whether the vaccine could produce rare side effects such as chest and heart inflammation that have been seen in mostly male older teenagers and young adults after the second dose.
The approval for younger children comes as Europe battles another massive surge of COVID-19 cases. Authorities in Austria, which is seeing a very high rate of infections, did not wait for EMA approval and have already begun vaccinating the 5 to 11 age group.
In Germany and the Netherlands, children now account for the majority of cases, and experts say that vaccinating them could be vital to bringing the fourth wave of the pandemic under control. COVID-19 death in Germany reached 100,000 on Thursday.